UNSPSC 51124404: Digoxin

This classification denotes a saponin and cardiotonic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 73K4184T59. European Medicines Agency schedules Digoxin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07135MIG. Digoxin generally arises in the molecular formula C41H64O14.

UNSPSC 51124404 Digoxin is a Commodity code encompassing specific pharmaceutical products supplied to state and local government health and emergency-response agencies. State and local governments procure digoxin and related cardiac medications under this code primarily for emergency medical services, public health programs, and institutional healthcare facilities. Recent solicitations show that issuing bodies are acquiring digoxin as part of broader advanced life support medication packages alongside complementary drugs such as epinephrine, adenosine, and diltiazem, often bundled in single competitive procurements rather than as standalone line items. Fire rescue departments, health and human services commissions, and cooperative purchasing alliances represent the primary buying entities, with issuing bodies ranging from city fire departments to state-level health agencies and multistate cooperative purchasing organizations.

Activity under this code appears concentrated in Florida and Minnesota with supporting engagement from Texas. The City of Tampa's Purchasing Department issued IFB 26P00188 in April 2026 for Advanced Life Support Medications including cardiac drugs for Tampa Fire Rescue, with a response deadline of April 8, 2026 and an estimated contract value of $40,000.00; the award carries a one-year term with two optional one-year renewals and includes a 5 percent bid discount for Small Local Business Enterprise participation. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 due March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with contract effectiveness July 1, 2026 and a two-year initial term. Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, seeking vendor capabilities for direct-to-manufacturer prescription programs, though this exploratory notice signals future procurement strategy rather than immediate buying activity under the digoxin code specifically.